Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.490
0.00 (0.00%)
At close: Feb 21, 2025, 4:00 PM
1.520
+0.030 (2.01%)
After-hours: Feb 21, 2025, 5:56 PM EST
Iterum Therapeutics Employees
Iterum Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 5 or -35.71% compared to the previous year.
Employees
9
Change (1Y)
-5
Growth (1Y)
-35.71%
Revenue / Employee
n/a
Profits / Employee
-$2,752,667
Market Cap
51.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ITRM News
- 16 days ago - Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 23 days ago - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - GlobeNewsWire
- 3 months ago - Iterum Therapeutics Regains Full Nasdaq Compliance - GlobeNewsWire
- 3 months ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 4 months ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire